A Phase 1 interventional study of Telmisartan 80mg and Chlorthalidone 25mg in Hypertension, sponsored by HanAll BioPharma Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-02-25.
Sponsored by HanAll BioPharma Co., Ltd. (part of Daewoong Pharmaceutical Co. LTD.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.
Among the 99 studies testing telmisartan in Hypertension, this one is the 78th largest by planned enrollment, is one of 2 that started in 2012, is one of 15 in phase 1, and was the 47th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:
Chong Kun Dang Pharmaceutical · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 20 Years to 50 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 5 · Phase 3 40 · Phase 4 32
First in 1997; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 184 across the 99 interventional studies. Of the 91 that completed or were terminated, 14 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 99 have an industry lead sponsor. The 10 most frequent:
This study is registered under HanAll BioPharma Co., Ltd., one of the names counted as Daewoong Pharmaceutical Co. LTD.. Under that name alone:
HanAll BioPharma Co., Ltd. is the lead sponsor of 16 studies on the registry; none are open to participants now.
15 studies in Hypertension by Daewoong Pharmaceutical Co. LTD.: 1 open now, 3 under way, none of them phase 3. Of 10 finished, 0 (0%) have results posted.
Among the 15 studies in Hypertension by Daewoong Pharmaceutical Co. LTD., this one is the 7th largest by planned enrollment of the 10 interventional ones that give a count, is one of 4 that started in 2012, is one of 4 in phase 1, and was the 3rd registered.
Daewoong Pharmaceutical Co. LTD.’s Hypertension studies by the year they started, since 2012.
None of the studies under way reaches primary completion within a year.
Among the 99 studies testing telmisartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Daewoong Pharmaceutical Co. LTD.’s 15 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Clinical trial to evaluate the pharmacokinetic interactions and safety between telmisartan and chlorthalidone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
telmisartan 80mg : multiple dose administered orally chlorthalidone 25mg : multiple dose administered orally
Drug: Telmisartan 80mg · Drug: Chlorthalidone 25mg
telmisartan 80mg : multiple dose administered orally chlorthalidone 25mg : multiple dose administered orally
Drug: Telmisartan 80mg · Drug: Chlorthalidone 25mg
Part A : AUC, Cmax of Telmisartan
Time frame: Over a 24-hour sampling period
Part B : AUC, Cmax of Chlorthalidone
Time frame: Over a 24-hour sampling period
Part A : Cmin, tmax, CL/F of Telmisartan
Time frame: Over a 24-hour sampling period
Part B : Cmin, tmax, CL/F of Chlorthalidone
Time frame: Over a 24-hour sampling period
The record gives a start of Nov 2012, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Telmisartan · Chlorthalidone